Plain-English translation of NCT06394492 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study compares a new medication called with standard chemotherapy treatments for women whose ovarian cancer has returned and no longer responds to platinum-based drugs. Researchers want to see whether this new medication may work better, work faster, or have fewer side effects than the chemotherapy options doctors typically use. About 440 women will participate, with half receiving the new medication and half receiving standard chemotherapy chosen by their doctor.
Ovarian cancer that comes back after platinum treatment is difficult to manage, and current chemotherapy options have limited effectiveness. Doctors need better treatment choices to help women in this situation live longer and have better quality of life.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the new medication or standard chemotherapy chosen by your doctor. You will visit the study center regularly for treatment infusions, blood tests, and imaging scans to monitor how your cancer is responding. Your doctor will watch you closely for side effects and adjust your care as needed throughout the study.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China